MarilynCPikeMDPhD
Rheumatology • Boston, MAAssociate Clinical Professor of Medicine, Massachusetts General Hospital
Dr. Pike is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yaw 2100 Rheumatology Associates
Boston, MA 02114Phone+1 617-726-2870Fax+1 617-726-2872
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 1984 - 1986
Duke University School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1994 - Present
NC State Medical License 2016 - 2025
MA State Medical License 1986 - 2019
MI State Medical License 1986 - 1990
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors Start of enrollment: 2003 Feb 01
Publications & Presentations
PubMed
- 87 citationsDeucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Eric Morand, Marilyn Pike, Joan T Merrill, Ronald van Vollenhoven, Victoria P Werth
Arthritis & Rheumatology. 2023-02-01 - 150 citationsEfficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controll...Megan E.B. Clowse, Daniel J. Wallace, Richard Furie, Michelle Petri, Marilyn C. Pike
Arthritis & Rheumatology. 2017-02-01 - 32 citationsLong‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension StudyDaniel J. Wallace, Kathryn Hobbs, Megan E.B. Clowse, Michelle Petri, Vibeke Strand
Arthritis Care & Research. 2016-04-01
Press Mentions
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022November 28th, 2022- Two Promising Treatment Options for SLENovember 16th, 2022
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
